CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [*****] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE THE REGISTRANT ACTUALLY TREATS THAT INFORMATION AS CONFIDENTIAL] REVENUE INTEREST PURCHASE AGREEMENT dated as of December 29, 2023 among...Revenue Interest Purchase Agreement • March 19th, 2024 • ImmunityBio, Inc. • Biological products, (no disgnostic substances) • New York
This REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of December 29, 2023, by and among ImmunityBio, Inc., a Delaware corporation (the “Company”), the Purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Purchaser Agent”).
REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • April 12th, 2024 • American Rebel Holdings Inc • Miscellaneous fabricated metal products • Texas
THIS REVENUE INTEREST PURCHASE AGREEMENT (the “Agreement”) is entered into effective as of the 8th day of April, 2024 (the “Effective Date”) by and between AMERICAN REBEL HOLDINGS, INC., a Nevada corporation (“AREB”) with an address of 909 18th Avenue South, Suite A, Nashville, Tennessee, 37212, for purposes of notice hereunder; and, CHRISTOPHER ANDREW CREWS, an individual (“Crews”), with an address of 2008 Freda Lane, Cardiff, CA 92007, for purposes of notice hereunder. AREB and Crews are sometimes referred to collectively herein as the “Parties”, and each individually as a “Party”.
REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • March 27th, 2024 • American Rebel Holdings Inc • Miscellaneous fabricated metal products • Texas
THIS REVENUE INTEREST PURCHASE AGREEMENT (the “Agreement”) is entered into effective as of the 22nd day of March, 2024 (the “Effective Date”) by and between AMERICAN REBEL HOLDINGS, INC., a Nevada corporation (“AREB”) with an address of 909 18th Avenue South, Suite A, Nashville, Tennessee, 37212, for purposes of notice hereunder; and, PETER WAGNER, a __________ _______ _______ _______ (“Wagner”), with an address of _____ ________ _______, ________ ___ _________, ______ _____, for purposes of notice hereunder. AREB and Wagner are sometimes referred to collectively herein as the “Parties”, and each individually as a “Party”.
REVENUE INTEREST PURCHASE AGREEMENT dated as of December 31, 2020 by and between PARATEK PHARMACEUTICALS, INC., as Seller, and PRTK SPV2 LLC, as CompanyRevenue Interest Purchase Agreement • January 4th, 2021 • Paratek Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • September 29th, 2021 • Mirum Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 (this “Amendment”) is entered into by and among Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Mulholland SA LLC, as Purchaser Agent for the Purchasers (in such capacity, the “Purchaser Agent”) and the Purchasers party to that certain Revenue Interest Purchase Agreement, dated as of December 8, 2020 (as amended, modified, restated or supplemented from time to time, the “RIPA”), effective as of September 28, 2021 (the “First Amendment Effective Date”).
REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • April 12th, 2024 • American Rebel Holdings Inc • Miscellaneous fabricated metal products • Texas
THIS REVENUE INTEREST PURCHASE AGREEMENT (the “Agreement”) is entered into effective as of the ___ day of April, 2024 (the “Effective Date”) by and between AMERICAN REBEL HOLDINGS, INC., a Nevada corporation (“AREB”) with an address of 909 18th Avenue South, Suite A, Nashville, Tennessee, 37212, for purposes of notice hereunder; and, STEVEN BUTLER, an individual residing in the State of California (“Butler”), with an address of 1332 Summit Ave., Cardiff, California, 92007, for purposes of notice hereunder. AREB and Butler are sometimes referred to collectively herein as the “Parties”, and each individually as a “Party”.
ContractRevenue Interest Purchase Agreement • May 11th, 2022 • Trevena Inc • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
REVENUE INTEREST PURCHASE AGREEMENT by and among ATNX SPV, LLC, ATHENEX, INC., Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Minn Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC, Oaktree-TBMR Strategic Credit Fund C, LLC, Oaktree-TBMR...Revenue Interest Purchase Agreement • July 29th, 2022 • Athenex, Inc. • Pharmaceutical preparations • New York
REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of June 21, 2022 (referred to herein as the “Effective Date”), by and among ATNX SPV, LLC, a Delaware limited liability corporation (“Seller”), Athenex, Inc., a Delaware corporation (“Parent”), Oaktree-TCDRS Strategic Credit, LLC, a Delaware limited liability company (“Oaktree TCDRS”), Oaktree-Minn Strategic Credit, LLC, a Delaware limited liability company (“Oaktree Minn”), Oaktree-Forrest Multi-Strategy, LLC, a Delaware limited liability company (“Oaktree Forrest”), Oaktree-TBMR Strategic Credit Fund C, LLC, a Delaware limited liability company (“Oaktree TBMR C”), Oaktree-TBMR Strategic Credit Fund F, LLC, a Delaware limited liability company (“Oaktree TBMR F”), Oaktree-TBMR Strategic Credit Fund G, LLC, a Delaware limited liability company (“Oaktree TBMR G”), Oaktree-TSE 16 Strategic Credit, LLC, a Delaware limited liability company (“O
LIMITED CONSENT AND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT December 10, 2024Revenue Interest Purchase Agreement • December 11th, 2024 • ImmunityBio, Inc. • Biological products, (no disgnostic substances)
This LIMITED CONSENT AND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT (this “Consent”), dated as of the date first set forth above, is entered into by and among ImmunityBio, Inc., a Delaware corporation (the “Company”), the Persons listed on the signature pages hereof under the heading “PURCHASERS”, which constitute the Required Purchasers in accordance with Section 8.08(a) of the Purchase Agreement (each a “Purchaser” and, collectively, the “Purchasers”), and Infinity SA LLC, a Delaware limited liability company, as collateral agent and administrative agent for the Purchasers (“Purchaser Agent”).
REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • April 25th, 2024 • American Rebel Holdings Inc • Miscellaneous fabricated metal products • Texas
THIS REVENUE INTEREST PURCHASE AGREEMENT (the “Agreement”) is entered into effective as of the 19th day of April, 2024 (the “Effective Date”) by and between AMERICAN REBEL HOLDINGS, INC., a Nevada corporation (“AREB”) with an address of 909 18th Avenue South, Suite A, Nashville, Tennessee, 37212, for purposes of notice hereunder; and, BERKE BAKAY, an individual (“Bakay”), with an address of 888 Prospect Street, Suite 200, La Jolla, California 92037, for purposes of notice hereunder. AREB and Bakay are sometimes referred to collectively herein as the “Parties”, and each individually as a “Party”.
REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • April 12th, 2024 • American Rebel Holdings Inc • Miscellaneous fabricated metal products • Texas
THIS REVENUE INTEREST PURCHASE AGREEMENT (the “Agreement”) is entered into effective as of the ____ day of April, 2024 (the “Effective Date”) by and between AMERICAN REBEL HOLDINGS, INC., a Nevada corporation (“AREB”) with an address of 909 18th Avenue South, Suite A, Nashville, Tennessee, 37212, for purposes of notice hereunder; and, JMSK BUTLER, LLC, a Colorado limited liability company (“JMSK”), with an address of 25430 Rainbow Ridge, Oak Creek, Colorado, 80467, for purposes of notice hereunder. AREB and JMSK are sometimes referred to collectively herein as the “Parties”, and each individually as a “Party”.
AMENDMENT NO. 1 TO REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • February 23rd, 2021 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 (this “Amendment”) is entered into by and among Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), Eiger Partners II LP (“Purchaser”) and Eiger III SA LLC, as collateral agent and administrative agent for the Purchasers (“Purchaser Agent”), effective as of November 9, 2020 (the “Effective Date”).
REVENUE INTEREST PURCHASE AGREEMENT DATED AS OF OCTOBER 19, 2022 BETWEEN INSMED INCORPORATED, AND ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LPRevenue Interest Purchase Agreement • October 27th, 2022 • INSMED Inc • Pharmaceutical preparations • New York
This REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of October 19, 2022, by and between Insmed Incorporated, a Virginia corporation (the “Company”), and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP (the “Purchaser”).
WAIVER AND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT May 8, 2024Revenue Interest Purchase Agreement • August 13th, 2024 • Humacyte, Inc. • Biological products, (no disgnostic substances)
This Waiver and Amendment to Revenue Interest Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Humacyte Global, Inc., a Delaware corporation (the “Company”), Humacyte, Inc., a Delaware corporation (the “Parent” and, together with the Company, the “Obligors” and each, an “Obligor”), the Persons listed on the signature pages hereof under the heading “PURCHASERS” (each a “Purchaser” and, collectively, the “Purchasers”), and Hook SA LLC, a Delaware limited liability company (“Purchaser Agent”).
REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • August 14th, 2023 • Humacyte, Inc. • Biological products, (no disgnostic substances) • New York
This REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of May 12, 2023, by and among Humacyte Global, Inc., a Delaware corporation (the “Company”), Humacyte, Inc., a Delaware corporation (the “Parent”), the Purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”) and Hook SA LLC, as collateral agent and administrative agent for the Purchasers (the “Purchaser Agent”).
AMENDMENT NO. 2 TO REVENUE INTEREST PURCHASE AGREEMENTRevenue Interest Purchase Agreement • April 26th, 2021 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 (this “Amendment”) is entered into by and among Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), Eiger Partners II LP (“Purchaser”) and Eiger III SA LLC, as collateral agent and administrative agent for the Purchasers (“Purchaser Agent”), effective as of April 26, 2021 (the “Second Amendment Effective Date”).
WAIVER AND AMENDMENT NO. 3 TO REVENUE INTEREST PURCHASE AGREEMENT AND AMENDMENT NO. 2 TO SECURITY AGREEMENTRevenue Interest Purchase Agreement • February 21st, 2023 • Esperion Therapeutics, Inc. • Pharmaceutical preparations
This Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (this “Amendment”) is entered into by and among Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), Eiger Partners II Fund, a sub-fund of Interlaken ICAV (“Purchaser”) and Eiger III SA LLC, as collateral agent and administrative agent for the Purchaser (“Purchaser Agent”), effective as of November 23, 2022 (the “Third Amendment Effective Date”).
